Crave for virtue as when thirsty is a common phenomenon in the bio-medical industry. While a post-80s doctor resolutely chose to abandon the favorable conditions of the German research center, leading an international top stem cell drug and gene editing research and development technical team, returned to Shenyang, Liaoning and established a stem cell drug research and development focused, high-tech Company. The doctor also established the Sino-German Regenerative Medicine Center, with the support of the Dadong District Government.
The person is a Distinguished Professor of Shenyang University of Chemical Technology, Yin Xiushan, who is also known as the Chairman of Biotech. Yin is very proud of his choice: “I feel very grateful to my alma mater. It’s my responsibility to contribute to the construction of my hometown. We choose to return to our hometown after advanced studies. We hope that through our efforts, we can promote the development and the rise of regenerative medicine, molecular biology, clinical medicine and other industries in Shenyang, adding icing to the construction and revitalization of Shenyang and the old industrial base in Northeast China."
In 2004, after graduating from Shenyang Institute of Chemical Technology, Yin Xiushan chose to study for a Ph.D. in the Academy of Military Medical Sciences. At that time, the Academy of Military Medical Sciences was following the development plan of “With the Master quality, gets major rewards, making mass achievements” put forward by Academician He Fuchu had reached fruitful results. The excellent atmosphere and great teachers affected Yin Xiushan’s future research career.
Because of his outstanding academic performance, after graduating in 2009, Yin went to the European Molecular Biology Laboratory in Heidelberg, Germany for embryonic stem cell research. Subsequently, he was allocated as the head of an independent research team at the University of Cologne Medical School in Cologne, Germany, where he was involved in the clinical transformation of tissue stem cells. In 2011, he conducted an in-depth study of stem cells at the Marx-Delbrück Center for Molecular Medicine in Berlin, Germany.
Last year, as a member of the Chunhui project initiated by the Ministry of Education of the Chinese Embassy in Germany, Yin Xiushan returned to his alma mater, Shenyang University of Chemical Technology, for academic exchanges with the support of the Sino-German Institute of Molecular Medicine and Molecular Pharmacy. “President Li Zhiyi, Vice President Xu Guangwen and Dean Zhang Wanzhong from the School of Pharmaceutical and Bioengineering warmly invited me to return to my alma mater to further my career. During the inspection tour of Guangzhou, Mayor Jiang Youwei appraised our stem cell research results. Under such opportunity, we decided to establish the transformation project company in Shenyang and settle our research team in Shenyang University of Chemical Technology. Under the trend of encouraging innovation and entrepreneurship in the country, we have carried out the two-way positioning", said Yin.
For the original intention of choosing to abandon Germany and return to Shenyang, Yin Xiushan said that it is a sentiment for the country, “…and I hope that my studies can serve the motherland and repay the society. Choosing to return to Shenyang, on the one hand, is a feeling for the alma mater, hoping to make a small contribution to the development of the university; on the other hand, because the Shenyang Municipal Government has given strong support in all aspects, it is also hoped that we can revitalize the Northeast, the old industrial base, and make some contributions."
Yin Xiushan's team currently set up the Bio-tech bio-medical technology limited company in Shenyang, a company founded by the Chinese team of Chinese scientists at the MDC National Molecular Biomedical Center in Germany, a high-tech enterprise dedicated to molecular diagnostics and biological cell therapy, develops, promotes, and industrializes bioengineering related technologies, such as gene editing technology on animals, plants and genetic engineering. The company is headquartered in Shenyang and its subsidiary is located in Berlin, Germany.
"Our company's current equipped software and hardware is no different from that in Germany or Sweden. We are confident that we can develop the company and make achievements that can stand up against other foreign countries." Yin Xiushan added.
At present, Bio-tech bio-medical technology limited company is mainly engaged in stem cell therapy, using genetic modification technology to produce second-generation mesenchymal stem cell drugs with independent intellectual property rights, targeting precise treatment of liver cirrhosis, osteoarthritis and stroke diseases. At the same time, the company is making progress on stem cell technology transforming and has established stem cells bank of endangered animals to protect biodiversity. By March 2019, the number of patent applications has reached 17 and it is planned to complete the laboratory development of two new biological drugs by the end of 2019.
After two years of technology landing and results transformation, in March this year, with the support of the Dadong District Government, the Sino-German Regenerative Medicine Center was built and put into use. (with deletion)
